COST EFFECTIVENESS OF ICATIBANT FOR HEREDITARY ANGIOEDEMA IN BRAZIL: CHALLENGES IN THE ECONOMIC EVALUATION OF ORPHAN DRUGS

Página do item simplificado
dc.contributor.authorMagliano, CA
dc.contributor.authorTura, BR
dc.contributor.authorSantos, M
dc.contributor.authorSenna, K
dc.contributor.authorCosta, MG
dc.date.accessioned2024-10-23T19:34:19Z
dc.date.available2024-10-23T19:34:19Z
dc.date.issued2016
dc.identifier.citationMagliano CA, Tura BR, Santos M, Senna K, Costa MG. COST EFFECTIVENESS OF ICATIBANT FOR HEREDITARY ANGIOEDEMA IN BRAZIL: CHALLENGES IN THE ECONOMIC EVALUATION OF ORPHAN DRUGS. VALUE IN HEALTH. 2016. doi: 10.1016/j.jval.2016.03.1066
dc.identifier.otherDOI: 10.1016/j.jval.2016.03.1066
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/531
dc.language.isoen
dc.publisherVALUE IN HEALTH
dc.titleCOST EFFECTIVENESS OF ICATIBANT FOR HEREDITARY ANGIOEDEMA IN BRAZIL: CHALLENGES IN THE ECONOMIC EVALUATION OF ORPHAN DRUGS
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Magliano CA et al _Value Health EN.pdf
Tamanho:
64.04 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente